Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies

Despite the remarkable success of autologous chimeric antigen receptor (CAR) T cells, some patients relapse due to tumor antigen escape and low or uneven antigen expression, among other mechanisms. Therapeutic options after relapse are limited, emphasizing the need to optimize current approaches. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Aranda-Orgilles, Beatriz, Chion-Sotinel, Isabelle, Skinner, Jordan, Grudman, Steven, Mumford, Ben, Dixon, Chantel, Postigo Fernandez, Jorge, Erler, Piril, Duchateau, Phillipe, Gouble, Agnes, Galetto, Roman, Poirot, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320475/
https://www.ncbi.nlm.nih.gov/pubmed/37257169
http://dx.doi.org/10.1158/2326-6066.CIR-22-0910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320475/
https://www.ncbi.nlm.nih.gov/pubmed/37257169
http://dx.doi.org/10.1158/2326-6066.CIR-22-0910

Ejemplares similares